XDEMVY Sales Jump 64% to $194.6M, but $632M IPR&D Charge Drives $668M Quarterly Loss
TARS sits 32% above its 52-week low of $53.89.
Summary
XDEMVY net product sales hit $194.6 million in Q3 2026, up roughly 64% from $118.7 million a year earlier, with gross margins steady near 93%. The top line keeps compounding off the Q2 print of $173.9 million, and management noted prescribing eye care professionals rose about 20% through the quarter while refills reached roughly 20% of prescriptions. The reported net loss of $668.3 million, or $14.40 per share, is almost entirely accounting: $632.2 million of acquired IPR&D expense from the iRenix ($81.0 million) and Alkeus ($551.2 million) deals, which were expensed because the programs have no alternative future use. Cash and marketable securities stood at $309.6 million at quarter-end, and the company also named Neera Clase Chief Commercial Officer. The real question for the stock is whether the underlying commercial trend holds into year-end; the pipeline readouts that matter are TP-04 Kore and TP-05 Calliope topline data, both expected in the first half of 2027.
At the time of this announcement, TARS was trading at $71.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $53.89 to $91.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.